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In the present study we demonstrate that human monocytes activated by lipopolysaccharides 
(LPS) were able to produce high levels of interleukin 10 (I1-10), previously designated cytokine 
synthesis inhibitory factor (CSIF),  in a dose dependent fashion.  I1-10 was detectable 7 h after 
activation of the monocytes and maximal levels of I1-10 production were observed after 24--48 h. 
These kinetics indicated that the production of Ibl0 by human monocytes was relatively late 
as compared to the production of IDiot, I1-1/3, I1.-6, I1-8, tumor necrosis factor ot(TNFot), and 
granulocyte colony-stimulating factor (G-CSF), which were all secreted at high levels 4-8 h after 
activation.  The production of I1-10 by LPS activated monocytes was, similar to that of ILlot, 
FL-1/3, l'b6, I1-8, TNFc~ granulocyte-macrophage colony-stimulating factor (GM-CSF), and G-CSF, 
inhibited by II-4. Furthermore we demonstrate here that I1-10, added to monocytes, activated 
by interferon 3r  LPS, or combinations of LPS and IFN-3' at the onset of the cultures, 
strongly inhibited the production of I1-1ot, I1-1B, I1-6, I1-8, TNFOt, GM-CSF,  and G-CSF at 
the transcriptional level. Viral-I1-10,  which has similar biological activities on human cells, also 
inhibited the production of TNFOt and GM-CSF by monocytes following LPS activation. Activation 
of monocytes by LPS in the presence of neutralizing anti-I1-10 monoclonal antibodies resulted 
in the production of higher amounts of cytokines relative to LPS treatment alone, indicating 
that endogenously produced I1-10 inhibited the production of I1-1ot, I1-1B, I1-6, I1-8, TNFot, 
GM-CSF,  and G-CSF.  In addition, I1-10 had autoregulatory effects since it strongly inhibited 
I1-10 mRNA synthesis in LPS activated monocytes. Furthermore, endogenously produced I1-10 
was found to be responsible for the reduction in class II major histocompatibility  complex (MHC) 
expression following activation of monocytes with LPS. Taken together our results indicate that 
I1-10 has important regulatory effects on immunological and inflammatory responses because 
of its capacity to down.regulate  class II MHC  expression  and to inhibit the production of 
proinflammatory cytokines by monocytes. 
M 
urine--IL-10 was recently identified and its gene cloned 
based on its cytokine synthesis inhibitory (CSIF) 1 ac- 
tivity (1, 2). In murine systems, I1-10 was produced by the 
CD4 + Th2  subset  and inhibits the cytokine production, 
particularly IFN-3', by Thl clones (1, 2). The inhibition of 
cytokine production by I1-10 was observed only when mac- 
rophages, but not when B cells were used as APCs (3). In 
addition to its CSIF activity, I1-10 was shown to be pleiotropic 
and to act on different cell types, including thymocytes (4), 
I Abbreviations used in this paper: CSIF, cytokine  synthesis  inhibitory  factor; 
G-CSF, granulocyte  colony-stimulating  factor; GM-CSF, granulocyte- 
macrophage colony-stimulating  factor; v-Ibl0, viral-IL-10. 
cytotoxic T cells (5), mast cells (6), B cells (7), and macro- 
phages (3). 
Human I1-10 also  exhibits CSIF activity (8).  We  have 
demonstrated that the production of IFN-'y and granulocyte- 
macrophage colony-stimulating factor (GM-CSF) by PBMC 
activated by PHA or anti-CD3 mAbs was strongly inhibited 
by ILl0 and that this inhibition occurred at the transcrip- 
tional level (8). Both human and routine I1-10 have extensive 
sequence  homology to a previously uncharacterized open 
reading frame in the Epstein Barr virus genome, BCRF-1 
(2, 8). Expression of the open reading frame yielded an ac- 
tive protein, designated viral-ILl0 (v-I1-10),  which shared 
most properties with human and routine Ibl0, including CSIF 
activity on mouse and human T  cells (9). 
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Volume 174  November  1991  1209-1220 Recently, we described that human II~10 and v-Ibl0 were 
able to inhibit antigen specific proliferative T  cell responses 
by reducing the antigen presenting capacity of human mono- 
cytes via downregulation  of class II MHC  molecules (9a). 
Here we describe that human monocytes were able to pro- 
duce high levels of IL-10 following activation with LPS and 
that this production was relatively late as compared to that 
of other monokines. In addition, it is reported here that IL-10 
strongly inhibited  the production of the proinflammatory 
cytokines IL-lo~, IL-1/3, IL-6, II~8,  and TNFot and the hae- 
matopoietic growth factors GM-CSF and granulocyte colony- 
stimulating factor (G-CSF) by monocytes activated by LPS, 
IFN-'y,  or LPS and  IFN-y.  Endogenously produced IL-10 
had not only autoregulatory effects on  IL-lct,  Ibl/3,  Ib6, 
II,8, TNFct, GM-CSF, and G-CSF production by monocytes, 
but also downregulated its own production and class II MHC 
expression on monocytes in an autoregulatory fashion. These 
results  indicate that  IL-10  has important  regulatory effects 
on immunological  and  inflammatory responses. 
Materials  and  Methods 
Isolation and Culture of Human Monocytes.  Human PBMs were 
isolated from 500 ml blood of normal donors as described previ- 
ously (10, 11). Mononuclear cells were isolated by density centrifu- 
gation in a blood component separator,  followed by fractionation 
into lymphocytes and monocytes by centrifugal elutriation. The 
monocyte preparation was >95% pure, as judged by nonspecific 
esterase staining and contained more than 98% viable cells. Mono- 
cytes were cultured in Yssel's medium (12) containing HSA sup- 
plemented with 1% pooled heat inactivated human AB + serum. 
This culture medium was  endotoxin free as determined by the 
Limulus amebocyte lysate assay (<0.2 ng/ml of endotoxin). The 
monocytes were cultured at a concentration of 4  x  l& cells/m1 
in teflon bags (Jansen MNL, St. Nildaas, Belgium), which prevented 
adhesion of these calls. After culture for the times indicated,  mono- 
cytes were collected and analyzed for cell surface expression by in- 
direct immunofluorescence or analyzed for lymphokine gene ex- 
pression  by Northern and PCR analysis. In addition, monocyte 
culture supernatants were collected for determination of Iblc~, IL-1B, 
IL-6, IL-8, Ibl0, TNFot, GM-CSF, and G-CSF production following 
activation of these ceils. The viability of the ceils after culture always 
exceeded 95%  as determined by trypan blue exclusion. 
Reagents.  Recombinant human IL-10 and v-Ibl0 were expressed 
in  Escherichia coli as  glutathione-S-transferase  fusion  proteins, 
purified, and digested with thrombin to remove the N-terminal 
fusion part (13), resulting in active human and v-IL-10 as described 
previously (9a). Purified human rlL-4 and rlFN-3' were provided 
by Schering-Plough Research (Bloomfidd, NJ). LPS (E. coli  0127:B8) 
was  obtained from Difco Laboratories (Detroit,  MI).  The neu- 
tralizing  anti-Ibl0  mAb  19F1 was  raised  against  v-IL-10  and 
efficiently neutralized both human and viral-Ibl0 (Silver, J., and 
J.  Abrams,  manuscript in preparation). 
Probes.  The following probes were used for northern analysis: 
600 bp Sma I fragment (nt 1299 - 1899) of pCD-hTGF/3 (14), 1200 
bp Pst I fragment of pAL (/3-actin) (8), 567 bp BamHI-Xba I frag- 
ment (nt 1 - 567) of pCD-hII_,6  (14), 268 bp Hind III fragment 
(nt 29 - 297) of SP64-3-10c (IL-8) (15), 760 bp Bgl II - Hind III 
fragment (nt 159 - 919) of pCD-SRot-hlL-10  (8).  The following 
oligonucleotides were used for Southern analysis of PCR products: 
IL-lot: 5'-CATGGGTGCTTATAAGTCATC-Y (nt 500-521) (16); 
IL-1/3: 5'-CGATCACTGAACTGCACGCTCCGGG-3' (nt 444 - 
469) (16); Ib6: 5'GAGGTATACCTAGAGTACCTC-Y (nt 510 - 531) 
(17); IL-8: 5'-TAAAGACATACTCCAAACCTT-3'  (nt 200 - 221) 
(15); IL-10: 5'-CAGGTGAAGAATCCTTTAATAAGCTCCAA- 
GAGA A AGGCATCTACA AAGCCATGAGTGAGTTTGACATC  - 
3' (nt 429 - 498) (8); TNF~: 5-GC~G~GAGCTGAGAGATAAC- 
3' (nt 500 - 521) (18); GM-CSF: 5'-CCGC~GTCTCCTGAACCT-Y 
(nt 150 - 168) (19); actin: 5'-C~AACCCTAAGGCCAACCGTG- 
3' (nt 250 - 272) (20); and G-CSF:  5'-GCCCTGGAAGGGATC- 
TCCCCC-Y  (nt 400 - 421) (21). 
mRNA Isolation and Northern Analysis.  Total ILNA was iso- 
lated from 20  x  106 monocytes by the guanidinium thioeyanate- 
CsC1 procedure (22). For northern analysis, 10/~g total tLNA per 
sample was separated  according to size on 1% agarose  gels con- 
raining 6.6% formaldehyde, transferred to Nytran nylon membranes 
(Schleicher & Schuell,  Keene, NH) and hybridized with probes, 
labeled  to high specific activity (>10  s cpm//~g) by the hexamer 
labeling technique (23). Filters were hybridized, washed under strin- 
gent conditions, and developed  as previously described (24). 
Polymerase Chain Reaction (PCR) Analysis.  1/xg of total tLNA 
was reverse transcribed using oligo (dT) 12-18 as primer (Boehringer 
Mannheim,  Indianapolis,  IN)  and  AMV  reverse  transcriptase 
(Boehringer Mannheim) according to the procedure of Krug and 
Berger (25) in a 20/zl reaction. 2/xl of reverse transcript (equivalent 
to 100 ng of total RNA) was used directly for each amplification 
reaction. Conditions for PCR were as follows: in a 50/~1 reaction, 
25 nmol of each primer, 125/~M each of dGTP, dATP, dCTP and 
dTTP (Pharmacia,  Uppsala, Sweden), 50 mM KC1, 10 mM Tris- 
HC1, pH 8.3, 1.5 mM MgC12, 1 mg/ml gelatin, 100/~g/ml non- 
acetylated BSA and 1 U Vent DNA polymerase (New England Bin- 
labs, Beverly, MA). Primers used were as follows: IL-lot sense primer 
5'-CATCGCCAATGACTCAGAGGAAG-Y  (nt 302-325),  Iblc~ 
antisense primer 5'-qroCCAAGCACACCCAGTAGTCTIV_K2TT-Y 
(nt 770 -  743)  (16),  IL-1B sense primer 5'-CCAGCTACGAAT- 
CTCGGACCACC-3'  (nt  230  -  253),  IL-1/J anti  sense  primer 
5'-TTAGGAAGACACAAATIV_~ATGGTGAAGTCAGT-3' (nt 896 
-  863)  (16),  11.-6 sense primer 5'-ATGAACTCCTTCTCCACA- 
AGC-3' (nt 1 - 21), Ib6 anti sense primer 5'-CTACATTTGCC- 
GAAGAGCCCTCAGGCTGGACTG-3'  (nt 810 - 777) (17), Ib8 
sense primer 5'-ATGACTTCCAAGCTGGCCGTG-3'  (nt 1 - 21), 
I1-8 anti sense primer 5'-TTATGAATTCTCAGCCCTCTTCAA- 
AAACTTCTC-Y (nt 302 - 269) (15), IL-10 sense primer 5'-ATG- 
CCCCAAGCTGAGAACCAAGACCCA-Y (nt 323 - 349), IL-10 
anti  sense  primer  5'-TCTCAAGGGGCTGGGTCAGCTATCC- 
CA-3'  (nt 674 -  648)  (8),  TNFc~  sense primer 5'-AGAGGGA- 
AGAGTTCCCCAGGGAC-Y  (nt 310 - 333),  TNFc~  anti sense 
primer 5'-TGAGTCGGTCACCCTTCTCCAG-Y (nt 782 - 760) 
(18), GM-CSF sense primer 5'-GCATCTCTGCACCCGCCCG- 
CTCGCC-3' (nt 76-100), GM-CSF anti sense primer 5'-CCTGC- 
TTGTACAGCTCCAGGCGGGT-Y  (nt 276 - 250)  (19), G-CSF 
sense primer 5'-GAGTGTGCCACCTACAAGCTGTGCC-Y (nt 
233  - 258),  G-CSF anti sense primer 5'-CCTGGGTGGGCTG- 
CAGGGCAGGGGC-3' (nt 533 - 508) (21),/~-actin sense primer 
5'-GTGGGGCGCCCCAGGCACCA-3' (nt 1 - 20), B-actin anti 
sense primer 5'-GTCCTTAATGTCACGCACGATTTC-3'  (nt 548 
- 530) (20). Reactions were incubated in a Perkin-Elmer/Cetus  DNA 
Thermal cycler for 20 cycles (denaturation 30 s 94~  annealing 
30 s 55~  extension 60 s 72~  Reactions were extracted with 
CHCI3 and 40/xl per sample was loaded on 1% agarose  gels in 
TAE buffer. Products were visualized by ethidium bromide staining. 
Subsequently, gels were denatured in 0.5 M NaOH, 1.5 M NaC1, 
neutralized in 10 M ammonium acetate, and transferred to Nytran 
nylon membranes. Membranes were pre-hybridized in 6  x  SSC, 
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Figure 1.  The kinetics of II-10, IL-6, TNFot, and GM-CSF production by human monocytes, activated by LPS. Human monocytes, isolated by cen- 
trifugal elutriation were cultured in teflon bags (4  x  lffS/ml) in the absence or presence of LPS (1 #g/ml) and production of (A) IL-10, (B) Ib6, 
(C) TNFoe and (D) GM-CSF was determined in the culture supernatants harvested at the times indicated by cytokine specific ELISA's. 
1% SDS, 10  x  Denhardt's solution (0.2% Ficoll, 0.2% polyvinyl- 
pyrrolidone, 0.2% BSA, pentax fraction V) and 200 #g/ml E. coli 
tRNA (Boehringer, Mannheim, FRG) for 4 h at 55~  Oligonu- 
cleotide probes (200 ng),  specific for a sequence internal  to the 
primers used in the amplification, were labeled at the 5' end by 
T4 polynucleotide kinase (New England Biolabs) and qr-3Zp-ATP 
(Amersham, Arlington Heights, IL) as described (26). Probes were 
separated from nonincorporated nucleotides by passage over a Nick 
column (Pharmacia) and added to the hybridization mix. Following 
hybridization for 12 h at 55~  filters were washed in 0.1  x  SSC 
(1  x  SSC:150 mM NaC1, 15 mM Na-citrate pH =  7.0),  1% SDS 
at room temperature and exposed to Kodak XAK-5 films for 1-2 h. 
Lymphokine Determinations.  The production oflL-lcr and TNFc~ 
by monocytes was measured by lymphokine specific ELIS~s ob- 
tained from Endogen  (Boston,  MA).  The lower detection limit 
of these ELISA's were 50 pg/ml and 10 pg/ml respectively.  Produc- 
tion of Ib13 was determined by lymphokine specific ELISA ob- 
tained from Cistron (Pine Brook, NJ). The sensitivity of this ELISA 
1211  de Waal Malefyt et al. was 20 pg/ml, lb6 levels were determined by lymphokine specific 
ELISA purchased from Genzyme (Boston, MA). The sensitivity 
of this assay was 0.313 ng/ml. Ib8 and G-CSF specific ELISA's 
were obtained from R&D Systems (Minneapolis, MN) and used 
to quantitate Ib8 and G-CSF production. The sensitivity of these 
ELISA's was 4.7 pg/ml and 7.2 pg/ml respectively.  GM-CSF produc- 
tion was determined by lymphokine specific ELISA as described 
previously (27). The sensitivity of this ELISA was 50 pg/ml. IL-IO 
production was determined by a specific  ELISA  in which the anti-IL- 
10 mAb JES 9D7 was used as a coating antibody and the anti-IL-10 
mAb JES3-12G8 as a tracer antibody (Silver,  J., and J. Abrams, 
manuscript in preparation). The sensitivity of this ELISA was 50 
pg/ml. 
Immunofluorescence Analysis.  Cells (10  s) were incubated in V 
bottom microtiter plates (Flow Laboratories, McLean, VA) with 
10/~1 of purified mAb (1 mg/ml) for 30 rain at 4~  After two 
washes with PBS containing 0.02 mM sodium azide and 1% BSA 
(Sigma Chemical Co., St. Louis, MO), the cells were incubated 
with  1/40 dilution  of FITC labeled F(ab')2 fragments  of goat 
anti-mouse  antibody (Tago, Inc., Burlingame, CA) for 30 min at 
4~  After three additional washes, the labeled cell samples were 
analyzed  by flow microfluometry on a FACScan (Becton Dickinson 
and Co., Sunnyvale, CA). The anti-MHC class II mAbs PdVS.2 
(HLA-DR/DP/DQ)  (28), Q5/13 HLA-DR/DP (29), and L243 
(HLA-DR) (30) were described previously. 
Results 
ILIO Is Produced by Human Monocytes.  We have shown 
previously that I1-10 was produced by activated human T 
cell clones, activated peripheral blood T  and B cells,  EBV 
transformed B cell lines (8) and monocytes (Abrams, J., H. 
Yssel, and M. G. Roncarolo, manuscript in preparation). Here 
we further characterize Ibl0 production by human mono- 
cytes.  Highly-purified human monocytes, isolated by cen- 
trifugal elutriation, produced I1.10 following activation by 
LPS. In addition, it is shown that these human monocytes 
were able to produce high levels of I1.6, TNFc~, and GM- 
CSF (Fig.  1). Kinetics of cytokine production by LPS acti- 
vated monocytes indicated that I1.10 production by mono- 
cytes was relatively late. It was first detected in supernatants 
harvested at 7.5 h, but maximal production was observed 
20-48 h after activation. In contrast, TNFol and I1-6 were 
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Figure 2.  The production  of ILl0 by human monocytes  in response 
to increasing concentrations  of LPS. Human monocytes  (4  x  106/ml) 
were cultured in teflon  bags with increasing concentrations of LPS for 
24 h and the production of Ib10 was determined by ELISA. 
produced rapidly upon activated and reached maximal levels 
of production  at 3.5 and 7.5 h following activation respec- 
tively (Fig. 1). However, GM-CSF production was also first 
detected 7.5 h after activation of monocytes by LPS, but in 
this case maximal production levels were reached at 20 h. 
Dose response studies indicated that activation ofmonocytes 
by LPS at 10 ng/ml already resulted in significant levels of 
11.10 production, whereas the maximal I1.10 synthesis was 
observed at LPS concentrations of 1 /zg/ml (Fig.  2). 
IL,  IO Inhibits Cytokine Production by Human Monocytes.  IL-10 
has been shown to inhibit IFN-3" and GM-CSF production 
by activated PBMC (8). To determine the effects of I1-10 on 
the production of cytokines by monocytes, highly-purified 
monocytes were activated for 24 h by LPS in the absence or 
presence of I1.10. In addition, monocytes were activated with 
Table  1.  Effects of Exogenous IL-IO, Endogenous IL-IO, and IL-4 on Cytokine Production by Human Monocytes 
IL-lt~  IL-I~  IL-6  IL-8  IL-10  TNFcr  GM-CSF  G-CSF 
ng/ml 
Medium  37~  0  0  0  150  0  0  0  0 
LPS  1.2  44.8  261.7  479  30.6  21.2  0.6  90 
LPS + IL-4  0  9.7  135.7  418  11.9  5.1  0  17.5 
LPS + IL-IO  0  13.6  78  434  ND  2.6  0  21.1 
LPS + alL- 10  2.7  50.6  323  672  ND  47.6  5.5  110 
Human monocytes, isolated by centrifugal  elutriation were cultured in teflon  bags at a concentration  of 4  x  106 ceUs/ml and activated  by LPS (1 
/zg/ml) in the absence and presence  of IL-10 (100 U/ml), IL-4 (100 U/ml) or anti-IL-10 mAb 19FI (10 #g/ml) for 24 h and production  of cytokines 
was determined in the supernatants by cytokine specific ELISA's. ND: not done. 
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Figure 3.  The effects of Ibl0 on the production of cytokines by mono- 
cytes activated by IFN-% LPS or LPS and IFN-% Human monocytes (4 
x  106/ml) were cultured with IFN-3, (100 U/ml), 1,  10, 100, or 1,000 
ng/ml LPS and combinations of LPS (1,  10,  100,  or  1,000 ng/ml) and 
IFN-'y (100 U/ml) either in the absence (E]) or presence ([]) of IblO (100 
U/ml) for 24 h and production of(A) Iblo~, (B) IL-1/~, (C) IL-6, (D) TNFo4 
and (E) GM-CSF was determined by cytokine specific ELISA's in the su- 
pernatants. 
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anti-Ibl0 mAb 19F1, which was raised against v-Ibl0 but 
efficiently neutralized both human I1:10 and v-IL-10 (Silver, 
J., andJ. Abrams, manuscript in preparation) (The latter results 
are discussed below). Cytokine production was determined 
in the supernatants of these cultures, harvested 24 h after ac- 
tivation, by cytokine specific ELISA's. As shown in shown 
in Table 1, monocytes  which were incubated in medium alone 
at 37~  did not produce I1:1c~, 11:1/3, I1:6,  Ibl0, TNFcr 
GM-CSF, and G-CSF. Under these conditions, only significant 
levels of I1:8 were synthesized. Activation of monocytes  with 
LPS (1/~g/ml) resulted in production of high levels of I1:1ol, 
Ib113, I1.-6, Ib8,  II:10, TNFot, GM-CSF,  and G-CSF.  In- 
terestingly,  IL-10 inhibited the production of I1:1o~, I1:1/3, 
I1:6, I1:8, TNFc~, GM-CSF, and G-CSF to various  extents 
(Table 1). The strongest inhibitory effects of I1.-10 were ob- 
served on the production of I1:1c~, TNFol, GM-CSF,  and 
G-CSF, which were blocked by 80-100%. The inhibition of 
I1:1/3 and I1:6 production was less pronounced, whereas the 
synthesis  of IL-8 was  only slightly affected by I1:10. 
ILI  O  Also Inhibits Cytokine Production of  Monocytes Activated 
by IFN-%  IL-10  also inhibited cytokine  production  by mono- 
cytes activated by IFN-% or combinations of IFN-3, and LPS. 
In Fig. 3, it is shown that IFN-3, at optimal concentrations 
of 100 U/ml generally was a less potent inducer of cytokine 
secretion than was LPS at optimal concentrations of I/~g/ml. 
Furthermore, it is demonstrated that the effects of combina- 
tions of IFN-3/and LPS on cytokine production by mono- 
cytes generally were additive. The strongest inhibitory effects 
of Ibl0 were observed on IL-la, TNFo~ and GM-CSF produc- 
tion. TNFc~ and GM-CSF secretion was suppressed by more 
than 90%, even following activation of the monocytes by 
optimal LPS and IFN-y concentrations. Although consider- 
able inhibitory effects on I1:1/3 and IL-6 secretion were ob- 
served at optimal stimulation conditions, their inhibition was 
more pronounced when the monocytes were stimulated by 
suboptimal concentrations of LPS, either in the absence or 
presence  of optimal concentrations of IFN-% 
Viral 11_,10  Inhibits Cytokine Production by Monocytes.  Viral 
I1:10 and human I1:10 have similar effects on human cells 
(9).  In Fig.  4, it is shown that both I1:10 and v-I1:10 in- 
hibited TNFc~ and GM-CSF production by monocytes in a 
similar fashion. I1:10 and v-I1:10, added at concentrations 
of 100 U/ml, had significant inhibitory effects on TNFo~ and 
GM-CSF production by monocytes following activation by 
LPS (1/zg/ml). These inhibitory effects of IL-10 and v-IL-10 
on TNF-o~ and GM-CSF secretion were reversed when incu- 
bations were carried out in the presence of mAb 19F1 (Fig. 
4), demonstrating the specificity of the inhibitory effects of 
v-I1:10. In fact, activation of monocytes by LPS in the pres- 
ence of I1:10 or v-IL-10 and the neutralizing anti-I1:10 mAb 
resulted even in enhanced production of TNFc~ and GM-CSF, 
indicating that endogenously produced Ibl0 suppressed the 
production of these cytokines. 
Endogenously Produced ILIO Inhibits Cytokine Production by 
Monocytes.  The inhibitory effects of endogenously  produced 
IL-10 on cytokine production by monocytes  was further evalu- 
Figure 4.  The effects of human Ibl0 and viral-Ibl0  on the production 
of TNF~ and GM-CSF by LPS activated monocytes. Human monocytes 
(4  x  106/ml) were activated by LPS (1/zg/ml) and cultured with human 
II.-10 (100 U/ml) or viral-IIr  in the absence or in the presence of neu- 
tralizing anti-IL-10 mAb 19F1 (10/~g/ml) for 24 h and production of (.4) 
TNFtx and (B) GM-CSF was determined  by cytokine specific ELISA's. 
ated by quantifying cytokine levels produced  by LPS activated 
monocytes in the presence of neutralizing anti-I1:lO mAb. 
In Table 1 it is shown that LPS plus anti-I1:10 treatment 
of monocytes resulted in higher levels of cytokine produc- 
tion as compared to activation by LPS alone, indicating that 
endogenously produced I1:10 in addition to its inhibitory 
effects on TNFcz and GM-CSF production  blocked the produc- 
tion of IL-lo~, I1:1/3, IL-6, IL8, and G-CSF.  The most sig- 
nificant inhibitory effects were found on the production of 
Ibla, GM-CSF, and TNF~ whereas the inhibitory effects 
on IL-1/3, I1:6,  IL-8, and G-CSF expression  were consider- 
able, but less pronounced. Taken together these results indi- 
cate that both exogenous I1-10 and endogenously produced 
I1:10 inhibit the production of I1:1c~, I1:1B, IL-6, 1I:8, TNF~ 
GM-CSF, and G-CSF by LPS activated  monocytes. 
11.4 Inhibits ILIO Production by Activated Monocytes.  We 
demonstrated previously that Ib4 inhibited production of 
IL-1/3, IL-6, and TNFc~ by LPS activated monocytes (31). To 
determine whether IL-4 also inhibited l-b10 production, mono- 
cytes were activated by LPS for 24 h and Ibl0 secretion was 
measured. As shown in Table 1, II.-4 strongly inhibited I1:10 
production by LPS activated monocytes. Furthermore, Ib4, 
1214  Interleukin 10 Inhibits Monokine Production Figure 6.  The effects of I1:10 on the expression of cytokine specific 
mKNA levels by human monocytes activated by LPS. mKNA was iso- 
lated from human monocytes (4  x  lO~/ml), activated by LPS (1 #g/ml) 
in the absence or presence of 11:10 (100 U/ml) for 7 h and expression  of 
I1:6, I1:8, Ibl0, TGF-/3,  and B actin was determined  by northern analyses. 
Figure 5.  The effects  of  exogenous  IL-10, endogenously  produced Ibl0 
and I1:4 on the expression of cytokine specific  mRNA levels  by human 
monocytes activated by LPS. Human monocytes (4  x  106/ml)  were cul- 
tured in medium at 4~  and 37~  or activated by LPS (1 mg/ml) in the 
absence or presence  of  II:4 (100 U/ml), I1:10  (100 U/ml) and neutralizing 
anti-IL-10 mAb 19F1 (10 #g/ml) and mKNA was isolated after 24 h. Ex- 
pression of/~-actin, I1:1o~, I1:1B, I1:6, I1:8, TNF-o~,  GM-CSF and G-CSF 
was determined on reverse transcribed mRNA by PCR analyses with 
cytokine specific  primers followed by Southern blotting  of the reaction 
products with internal probes, cDNA obtained from a CD4 + T cell clone 
was included as control for expression of TNFol and GM-CSF. 
in addition to its inhibitory effects on IL-I~, Ib6, and TNFcr 
secretion, efficiently blocked the production of GM-CSF and 
G-CSF.  However,  as observed for IL-10,  the production of 
IL-8 was only slightly affected by IL-4. CoUectively these data 
indicate that IL-4 and Ibl0 have comparable inhibitory effects 
of cytokine production by activated monocytes. 
Inhibition of  Monokine Production Occurs  at the Transc@tional 
Level.  To determine at which level Ib10 inhibited the produc- 
tion of cytokines by monocytes, comparative PCK analyses 
were performed on KNA isolated from monocytes, activated 
by LPS in the absence or presence of IL-10,  IL-4 or the neu- 
tralizing  anti-IL-10 mAb  for 24 h.  The cytokine measure- 
ments of this experiment are shown in Table 1. mKNA iso- 
lated from these samples was reverse transcribed into cDNA 
and  subsequently amplified with cytokine specific primers. 
A relatively small number of cycles was used for amplification 
to ensure that  the amount  of amplified DNA  was propor- 
tional to the cycle number and correlated with the amount 
of specific mRNA in the original sample. It is shown in Fig. 
5 that under these conditions equivalent amounts of/~-actin 
specific cDNA were amplified. Monocytes incubated at 4~ 
in medium alone for 24 h  expressed very low levels of IL-8 
mRNA.  Incubation of these cells at 37~  resulted in an in- 
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dogenously  produced  II.-10  and Ib4 on the ex- 
pression of IL-IO and TGFI3 specific mRNA 
levels by human monocytes  activated  by LPS. 
Human monocytes  (4  x  106/ml) were cul- 
tured in medium  at 4~  and 37~  or activated 
by LPS (1 mg/ml) in the absence or presence 
oflb4 (100 U/ml), II-10  (100 U/ml) and neu- 
tralizing  anti-Ibl0 mAb 19F1 (10/~g/ml)  and 
mRNA was isolated  after 24 h. Expression  of 
(/1) Ibl0, TGFB  and 13-actin was determined 
by northern  analyses  and (B) expression of IL- 
10  was  determined on  reverse transcribed 
mRNA by PCR analysis  with  cytokine  specific 
primers followed  by Southern blotting of the 
reaction products with internal probes. 
creased expression  of IL-8 mRNA, but did not induce ex- 
pression of IL-lc~, IL-113, IL-6, IL-10, TNF~  GM-CSF,  or 
G-CSF mRNA. LPS activation resulted in a strong expres- 
sion of II.-lo~, IL-113, IL-6, IL-8, and G-CSF mRNA, whereas 
TNFc~ and GM-CSF mRNA were moderately induced. Fur- 
thermore, it is shown in Fig. 5 that IL-lc~, I1.-6, TNF~ GM- 
CSF, and G-CSF expression  was strongly inhibited by IL-10 
and II.-4 at the mRNA level (Fig. 5), whereas IL-13 and II:8 
expression  were only slightly affected by IL-10. Activation 
of monocytes by LPS in the presence of the anti-IL-10  mAb 
resulted in a moderate enhancement in expression  of IL-lc~, 
IL-113, IL-6, IL-8, and G-CSF mRNA and a strong increase 
in TNFo~ and GM-CSF mRNA synthesis. The levels of ex- 
pression of cytokine specific mRNA and their modulation 
by exogenous and endogenous IblO or IL-4 correlated well 
with secretion of the corresponding proteins as shown in Table 
1 and indicated that IL-10 and IL-4 inhibited cytokine expres- 
sion by LPS activated monocytes at the transcriptional level. 
IL-IO Regulates 11_,10 mRNA  but not TGF/3 mRNA  Ex- 
pression in Activated Monocytes.  Having demonstrated that 
human monocytes produced IL-10 relatively late following 
activation by LPS, we determined whether II.-10 could affect 
endogenous IL-10 mRNA synthesis. Human monocytes were 
activated by LPS in the presence or absence of IL-10 for 7 h 
and mRNA expression  was analyzed by northern blotting. 
In Fig. 6 it is shown that IL-10 mRNA was detected 7 h 
after activation by LPS and that IL-10 had no or only min- 
imal inhibitory effects on IL-IO  mRNA expression at this time 
point. In contrast, the expression  of IL-6 and IL-8 mRNA 
was strongly inhibited by IL-10. However, in another series 
of experiments where monocytes were activated for 24 h by 
LPS, Ibl0 strongly reduced the expression  of IIr  ml~NA 
as shown by northern analysis in Fig. 7. Furthermore, it is 
shown in Fig. 7 that activation of monocytes with LPS in 
the presence of a neutralizing anti-IL-10 mAb resulted in an 
upregulation of I1.-10 mRNA expression at 24 h. These results 
were confirmed by PCR analysis with Ibl0 specific primers 
since the RNA used in this latter experiment was also used 
for the PCR analyses shown in Fig. 5. It is shown in Fig.  7 
B that the quantitative differences observed in II~10 mRNA 
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Figure 8.  The effects of endogenously produced IL-10  on class II MHC 
expression by human monocytes, activated with LPS. Human monocytes 
were cultured with (A) 0 ng/ml LPS, (B) 0.1 ng/ml LPS, (C) 10 ng/ml 
LPS, or (D) 1,000 ng/ml LPS in the absence or presence of neutralizing 
anti-IL-10 mAb 19F1 (10 mg/ml) for 40 h and expression of HLA-DR/DP 
(Q5/13) was determined by indirect immunofluorescence. 
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expression by Northern analysis correlated with those ob- 
served by comparative PCR analysis. In addition, the more 
sensitive PCR analysis allowed the detection of low levels 
of I1,10 mRNA that were induced 24 h after culture of mono- 
cytes in medium alone at 37~  These results indicate that 
I1,10 has autoregulatory effects on I1,10 mRNA synthesis 
and if mRNA levels accurately reflect I1,10 protein produc- 
tion, probably on I1,10 production by human monocytes as 
well. However, downregulation of I1,10 production occurred 
rather late in the activation process. TGF/3 mKNA, which 
was expressed constitutively in freshly isolated non activated 
monocytes, was not enhanced by LPS activation for 7 or 24 h 
(Figs. 6 and 7). In addition, it is shown in Figs. 6 and 7 that 
the levels of TGF/~ mRNA were not affected when activa- 
tions were carried out in the presence of I1,4, I1,10, or neu- 
tralizing anti-I1,10 mAbs. 
11,10 Has Autoregulatory Effects on Class II MHC Expres- 
sion by Monocytes.  Recently, we demonstrated that I1,10 
downregulated the expression of class II MHC molecules on 
the cell surface of human monocytes (ga). I1,10 was shown 
to downregulate constitutive, I1,4 or IFN-3'-induced MHC 
class II expression.  Since monocytes produce high levels of 
I1,10 following activation by LPS, the possibility that en- 
dogenous I1,10 could inhibit class II MHC expression by LPS 
activated monocytes was investigated.  Monocytes were acti- 
vated by various  concentrations of LPS in the presence or 
absence of the neutralizing anti-I1,10 mAb. In Fig.  8 it is 
shown that activation of monocytes with LPS reduced the 
constitutive HLA-DK/DP expression on these cells in a dose 
dependent manner. However,  in the presence  of the neu- 
tralizing anti-I1,10 mAb 19F1 strong induction of HLA- 
DK/DP expression was observed. Identical results were ob- 
tained with several HLA-DR or HLA-DK/DP specific mAb. 
These results indicate that endogenously produced I1,10, in 
an autoregulatory fashion, was responsible for the downregu- 
lation of class II MHC expression on human monocytes fol- 
lowing LPS activation. 
Discussion 
In the present study we demonstrated that human IL-10 
was produced in relatively large quantities by monocytes fol- 
lowing activation.  Kinetic studies showed that low levels of 
1I.,10 could be detected 7 h after activation of the monocytes, 
and maximal II.,10 production occurred 24-48 h after activa- 
tion. This was relatively late as compared to the production 
of I1,1oe, I1,1/~, I1,6, I1,8 and TNF-o~, which were secreted 
at high levels between 4-8 h after activation (31-33).  In ad- 
dition, we showed that human I1,10 has strong inhibitory 
effects on cytokine production by monocytes following acti- 
vation with IFN-'y, LPS or combinations of IFN-3' and LPS. 
These inhibitory effects are specific for I1,10 since they could 
be completely neutralized by mAb 19F1 which inhibits both 
I1,10 and v-I1,10 activity.  II.,10 added at concentrations of 
100 U/ml reduced IDlol, TNF-ol, GM-CSF, and G-CSF syn- 
thesis by more than 90% following optimal activation of the 
monoeytes by combinations of IFN-'y (100 U/ml) and LPS 
(1 #g/ml). The inhibitory effects on II,13,  I1,6,  and I1,8 production were somewhat less pronounced, particularly when 
the monocytes were optimally activated by combinations of 
IFN-~/and LPS. The mechanism  by which ID10 inhibits 
cytokine production by monocytes is not clear. It remains 
to be determined whether these effects of ILl0 are direct or 
indirectly mediated via other factors. Since IL-1 can induce 
IL-6 production in fibroblasts, thymocytes,  and monocytes 
(34-36),  it is, for example, possible that the partial inhibi- 
tion of ID6 production is the result of  reduced Ibl production. 
Viral-IL-10 which has been shown to possess biological 
activities, on human cells similar to human IL-10 (9), was 
less extensively tested. However, v-Ibl0 inhibited TNFoL and 
GM-CSF production by LPS activated monocytes to the same 
extent as did human Ibl0. These inhibitory effects of v-Ib 
10 on TNFol and GM-CSF production were neutralized by 
mAb 19F1, illustrating  the specificity of the v-Ibl0 effects. 
Inhibition of Ibhx, IL-lfl, Ib6, 11.-8, TNF-ol, GM-CSF, 
and G-CSF secretion occurred at the transcriptional level. IL-10 
strongly inhibited cytokine specific  mRNA synthesis induced 
by LPS, as determined by northern and PCR analyses. PCR 
analyses were performed under conditions that allowed a com- 
parison of the reaction products of individual  samples in a 
semiquantitative manner. This was validated by the fact that 
amplification  of cDNA's with primers  specific for fl-actin 
resulted in equivalent amounts of reaction products between 
the samples and quantitatively  comparable results were ob- 
tained when IL-10 mRNA expression was determined in the 
same samples by both northern and PCR analysis. In addi- 
tion, cytokine mRNA expression levels correlated with the 
protein levels in the supernatants of these cultures. Ibl0 failed 
to affect TGF-fl mRNA expression in activated monocytes. 
However, it has to be noted here that TGF-fl was constitu- 
tively expressed in nonactivated monocytes and that activa- 
tion of the monocytes by LPS did not affect TGF-fl mRNA 
levels. Assoian et al. (37) have demonstrated that monocytes 
constitutively express TGF-fl mRNA and that TGF-fl secre- 
tion requires monocyte activation.  However, it remains to 
be determined whether Ibl0 has an effect on the conversion 
of TGF-fl from its latent to its  active form. 
The production of IL-10 was shown to be inhibited by Ib4 
at the transcriptional  level. Although the inhibitory effects 
of I1.-4 on Ibl0 production were considerable, IL-4 was not 
able to block the production of I1.-10 completely. IL-4 inhibited 
the production of IL-10 only up to 70%,  even when high 
ID4 concentrations (400 U/ml), which were su~dent to com- 
pletely inhibit the production of Ibl, Ib6, and TNF~ were 
used (results not shown). We (31) and others (38-40)  have 
demonstrated previously that II_,4 was able to inhibit  the 
production of IL-lot, IDlfl, IL-6, IL-8 (41), and TNFc~ by 
human monocytes. These findings were confirmed here and 
extended by demonstrating that IL-4 also inhibited the produc- 
tion of IbS, GM-CSF, and G-CSF by LPS activated human 
monocytes.  This inhibition occurred at the transcriptional 
level. The data furthermore illustrate that IL-4 and Ibl0 have 
similar effects on cytokine expression by human monocytes, 
which underlines the pleiotropic effects  of cytokines and redun- 
dancy in the immune system. 
Interestingly, II.-10 is an autoregulatory cytokine, since it 
strongly inhibited IL-10 mRNA synthesis in monocytes acti- 
vated for 24 h. In addition,  activation of monocytes by LPS 
in the presence of neutralizing anti-Ibl0 mAbs resulted in 
an increased expression of IL-10 mRNA at 24 h, indicating 
that endogenously produced Ibl0 also inhibited Ibl0 mRNA 
synthesis. The fact that Ibl0 is able to downregulate its own 
production by human monocytes makes  this the first cytokine 
that is regulated by a negative  feedback mechanism.  Au- 
toregulatory  effects  of  endogenously produced ID10 were also 
observed on the production of Iblcx, Iblfl, Ib6, ID8, TNF-c~, 
GM-CSF, and G-CSF by LPS activated monocytes. However, 
the inhibitory effects of endogenous IL-10 on the production 
of these cytokines were less pronounced than those of exoge- 
nous Ibl0 added at the onset of the culture. This is related 
to the fact that Iblot, IL-lfl, IL-6, IL-8, TNF-ot, and G-CSF 
are already produced at high levels 4-8 h after activation, 
whereas maximal endogenous Ibl0 production occurs much 
later at 24-48 h after activation.  This notion is supported 
by the observation that the strongest inhibitory effects of en- 
dogenously produced IL-10 were found on GM-CSF secre- 
tion which was shown to be produced late following activa- 
tion of the monocytes. Assuming that Ibl0 mRNA synthesis 
reflects and precedes Ibl0 protein secretion, and that Ibl0 
can only interact with its receptor on the cell surface, these 
results suggest  that the inhibitory effects of endogenously 
produced Ibl0 occur relatively late and may therefore be of 
particular importance in the later phases of an immune re- 
sponse. 
IL-10 was first described in the mouse as a CSIF produced 
by Th2  cells, which inhibited cytokine production  (pre- 
dominately IFN-3' by Thl cells (1). This inhibitory effect of 
mouse-IL-10 on cytokine production by Thl cells required 
the presence of macrophages (3). Recently we demonstrated 
that  human IL-10 and v-IL-10 strongly inhibited antigen 
specific T  cell proliferation  when monocytes were used as 
APC (9a). In addition,  it was shown that reduction in the 
antigen specific proliferative T cell responses were for a major 
part due to the reduced antigen presenting  capacity of the 
monocytes caused by strong downregulatory effects of I[rl0 
on class II MHC antigen expression on these cells. These 
data, together with the present finding that IL-10 is produced 
late by monocytes and has autoregulatory effects  on IL-10 secre- 
tion by these ceils, indicate that IL-10 may have strong down- 
regulatory effects  on ongoing antigen specific  T cell responses. 
Therefore IL-10 may be a cytokine that plays a major role 
in dampening antigen driven proliferative T cell responses. 
The notion, that IL-10 produced by monocytes may also have 
strong autoregulatory feedback activity on T cell activation, 
is supported by the observation that IL-10 produced by mono- 
cytes following activation by LPS is responsible for down- 
regulation of class II MHC antigens on these cells, since class 
II MHC expression was not reduced and even strongly en- 
hanced when LPS stimulations were carried out in the pres- 
ence of the neutralizing anti-II.rl0 mAh. 
The finding that IL-10 has strong downregulatory effects 
on the secretion of the proinflammatory cytokines ILoloe, IL- 
1218  lnterleukin  10 Inhibits Monokine Production lfl, IL-6, Ib8,  and TNF-c~ which are all involved in acute 
and chronic inflammatory processes, many autoimmune dis- 
eases, including rheumatoid arthritis and not only modulate 
the activation and function of cells of the immune system 
but also those of endothelial cells, keratinocytes and hepato- 
cytes (42-44), suggests that II.-10 is a powerful inhibitor of 
inflammation. Based on its properties described thus far, which 
include inhibition of antigen specific T cell proliferation by 
reducing the APC capacity of monocytes through downregu- 
lation of class II MHC antigens on these cells and inhibitory 
effects on proinflammatory cytokine secretion by monocytes, 
it seems that II,-10 plays a major role as a suppressor  of im- 
mune and inflammatory responses. 
The authors thank Dr. Kevin Moore (DNAX)  for stimulating discussions, Dr. Anje te Velde and Mr. 
Richard Huijbens for isolation of monocytes and excellent technical support, Dr. Rob Kastelein and Ms. 
Karen  Johnson for providing recombinant 11,-10 and v-IL-10, and Mrs. Janet Dillon for excellent secretarial 
assistance. 
The DNAX Research Institute of Molecular and Cellular Biology is supported by Schering-Plough Cor- 
poration. 
Address correspondence  to Jan E. de Vries, Human Immunology  Department, DNAX Research Institute, 
901 California Avenue, Palo Alto, CA 94304-1104. 
Received for publication 24 June  1991. 
References 
1.  Fiorentino, D.F., M.W. Bond, and T.R. Mosmann. 1989. Two 
types of mouse T helper cell. IV. Th2 clones secrete a factor 
that inhibits cytokine production by Thl clones.J. ExI~ Med. 
170:2081. 
2.  Moore, K.W., P. Vieira, D.F. Fiorentino,  M.L. Trounstine,  T.A. 
Khan, and T.R. Mosmann. 1990. Homology  of cytokine syn- 
thesis inhibitory factor (I1.-10) to the Epstein-Barr virus gene 
BCRF1. Science (Wash. DO.  248:1230. 
3.  Fiorentino, D.F., A. Zlotnik, P. Vieira, T.R. Mosmann, M. 
Howard, K.W. Moore, and A. O'Garra.  1991. 1I.,10 acts on 
the antigen presenting cell to inhibit cytokine production by 
Thl cells.  J. Iramunol. 146:3444. 
4.  MacNeil, I.A., T. Suda, K.W. Moore, T.R. Mosmann, and 
A. Zlotnik.  1990. Ilrl0, a novel growth cofactor for mature 
and immature T cells.  J. lmmunoL 145:4167. 
5.  Chen, W.F., and A. Zlotnik.  1991. Ibl0: A novel cytotoxic 
T cell differentiation factor. J. lmmunol. 147:528. 
6.  Thompson-Snipes,  L.A., V. Dhar, M.W. Bond, T.R. Mosmann, 
K.W. Moore, and D.M. Rennick. 1991. Interleukin 10: A novel 
stimulatory factor for mast cells and their progenitors.J. Exp. 
Med. 173:507. 
7.  Go, N.F., B.E. Castle, R. Barrett,  R. Kastelein, W. Dang, 
T.R. Mosmann, K.W. Moore, and M. Howard. 1990. Inter- 
leukin 10, a novel B cell stimulatory factor: Unresponsiveness 
of X chromosome linked immunodeficiency B cells.  J. Exp. 
Med. 172:1625. 
8.  Vieira, P., R. de Waal Malefyt, M.-N. Dang, K.E. Johnson, 
R. Kastelein,  D.F. Fiorentino,  J.E. de "Cries, M.-G. RJoncarolo, 
T.R. Mosmann, and K.W. Moore. 1991. Isolation and expres- 
sion of human  cytokine synthesis inhibitory  factor cDNA 
clones: Homology to Epstein-Barr virus open reading frame 
BCRF1. Proa Natl. Acad. Sci. USA.  88:1172. 
9.  Hsu,  D.-H.,  R. de Waal Malefyt, D.F. Fiorentino, M.-N. 
Dang, P. Vieira, J.E. de Vries, H. Spits, T.R. Mosmann, and 
K.W. Moore. 1990. Expression of interleukin-10 activity by 
Epstein-Barr virus protein BCRF1. Science  (Wash. DC). 250:830. 
9a.de Waal Malefyt, R., J. Haanen, H. Spits, M.-G. Roncarolo, 
A. te Velde, C. Figdor, K. Johnson, R. Kastelein, H. Yssel, 
and J.E. de Vries. 1991. Interleukin 10(IL-10) and viral IL-10 
strongly reduce antigen-specific  human T cell proliferation by 
diminishing the antigen-presenting capacity of monocytes via 
downregulation of dass II major histocompatibility complex 
expression, j. Ex  F Med. 174:915. 
10.  Fidgor, C.G., W.S. Bont, I. Touw, D. Roos, E.E. Roosnek, 
and J.E.  De Vries. 1982. Isolation of functionally different 
human monocytes by counterflow centrifugation elutriation. 
Blood. 60:46. 
11.  Figdor,  C.G., W.L. van Es, J.M.M. Leemans,  and W.S. Bont. 
1984. A centrifugal elutriation  system of separating small 
numbers of cells. J. Immunol. Methods. 68:73. 
12.  Yssel, H., J.E. de "Cries, M. Kohen, W. van Blitterswyk, and 
H. Spits. 1984. Serum free medium for generation and propa- 
gation of functional human cytotoxic and helper T cell clones. 
J. Immunol. Methods. 72:219. 
13.  Smith, D.B., and K.S. Johnson. 1988. Single step purification 
of  polypeptides  expressed in E. coli as fusions with glutathione- 
S-transferase. Gene. 67:31. 
14.  Yokota, T., F. Lee, N. Arai, D. Rennick, A. Zlotnik, T. Mos- 
mann, A. Miyajima, Y. Takabe, R. Kastelein, G. Zurawski, 
and K. Arai. 1987. Strategies for cloning mouse and human 
lymphokine  genes  using a mammalian  cDNA expression  vector. 
In Lymphokines.  D.W. Goeddel, and D.W. Webb, editors. Ac- 
ademic Press, New York. 1-26. 
15.  Schmid, J., and C. Weissmann. 1987. Induction of mRNA 
for a serine protease and a b-thromboglobulin-like protein in 
mitogen-stimulated human leukocytes.  J. Immunol. 139:250. 
16.  March, C.J., B. Mosley, A. Larsen, D.P. Cerretti, G. Braedt, 
V. Price, S. Gillis, C.S. Henney, S.R. Kronheim, K. Grabstein, 
P.J. Conlon, T.P. Hopp, and D. Cosman. 1985. Cloning, se- 
quence, and expression of two distinct human interleukin-1 
1219  de Waal Malefyt  et al. complementary DNAs.  Nature (Lond.). 315:641. 
17.  Hirano, T., K. Yasukawa, H. Harada, T. Toga, Y. Watanabe, 
T. Matsuda, K. Kashiwamura, K. Nakajima, K. Koyoma, A. 
Iwamatsu,  S. Tsunasawa, F. Sakiyama, H. Matsui,  Y. Taka- 
horn, T. Taniguchi, and T. Kishimoto. 1986. Complementary 
DNA for a novel human interleukin (BSF-2) that induces B 
lymphocytes to produce immunoglobin. Nature (Long). 324:73. 
18.  Pennica, D., G.E. Nedwin, J.S. Hayflick, P.H. Seeburg, R. 
Derynck, M.A. Palladino, W.J. Kohr, B.B. Aggarwal, and D.V. 
Goeddd. 1984. Human tumour necrosis factor: precursor struc- 
ture, expression, and homology  to lymphotoxin. Nature (Lond.). 
312:724. 
19.  Lee,  F., T. Yokota, T. Otsuka, L. Gemmell, N. I.arson, J. Luh, 
K. Arai, and D. Rennick. 1985. Isolation ofcDNA for a human 
granulocyte-macrophage colony-stimulating-factor by func- 
tional expression  in mammalian cells. Pro~ Natl. Acad. Sci. USA. 
82:4360. 
20.  Alonso, S., A. Minty, Y. Bourlet, and M. Buckingham. 1986. 
Comparison  of three actin-coding sequences in the mouse: 
Evolutionary relationships between the actin genes of warm- 
blooded vertebrates. J. Mol. Evol. 23:11. 
21.  Nagata, S., M. Tsuchija, S. Asano, Y. Kaziro, T. Yamazaki, 
O. Yamamoto, Y. Hirata, N. Kubota, M. Oheda, H. Nomura, 
and M. Ono. 1986. Molecular cloning and expression  ofcDNA 
for human granulocyte  colony-stimulating  factor. Nature (Lond.). 
319:415. 
22.  Chirgwin, J.M., A.E. Przybyla, R.J.  MacDonald, and W.J. 
Rutter.  1979. Isolation of biologically active ribonucleic acid 
from sources enriched in dbonuclease. Biochemistry. 18:5294. 
23.  Feinberg, A.P., and B. Vogelstein. 1983. A technique for radio- 
labeling DNA  restriction  endonuclease fragments  to  high 
specific activity. Anal.  Biochem. 132:6. 
24.  De Waal Malefyt, R., B. Alarcon, H. Yssd, J. Sancho, A. 
Miyajima, C. Terhorst, H. Spits, and J.E. de Vries. 1989. In- 
troduction of T cell receptor (TCR)-~ cDNA has differential 
effects  on TCR-3'~/CD3 expression  by PEER and Lyon-1  cells. 
j. Immunol.  142:3634. 
25.  Krug, M.S., and S.L. Berger. 1987. First strand cDNA syn- 
thesis primed with oligo (dT). Methods Enzymol.  152:316. 
26.  Maniatis, T., J. Sambrook, and E.F. Fritsch. 1989. Molecular 
Cloning:  A  Laboratory Manual. eds. Cold Spring  Harbor 
Laboratories, Cold Spring Harbor,  NY. pp. 545. 
27.  Bacchetta, R., R. de Waal Malefyt, H. Yssel, J. Abrams, J.E. 
de Vries, H. Spits, and M.G. Roncarolo. 1990. Host-reactive 
CD4 + and CD8 + T cell clones isolated from a human chi- 
mera produce IL-5, Ib2, IFN-% and granulocyte/macrophage- 
colony-stimulating factor but not IL-4.  j. Immunol.  144:902. 
28.  Koning,  F.,  G.M.T.H.  Schrender, M.  Giphart,  and  J.W. 
Bruning. 1984. A mouse monoclonal antibody detecting a DR- 
related MT2-1ike specificity:  Serology and biochemistry. Hum. 
ImmunoL  9:221. 
29.  Quaranta,  V., L.E. Walker, M.A.  Pelligrino, and S. Ferrone. 
1980. Purification of immunologically functional  subsets of 
human h-like antigens on a monoclonal antibody (Q5/13) im- 
munoadsorbent. J. ImmunoI. 136:2348. 
30.  Lampson, L.A., and R. Levy. 1980. Two populations of In-like 
molecules on a human  B cell line. J. Imraunol. 125:293. 
31.  te Velde, A.A.,  R.J.F. Huijbens, K. Heije, J.E. de "Cries, and 
C.G. Figdor. 1990. Interleukin  4 (IL-4) inhibits secretion of 
IIH/3, tumor necrosis factor-a, and ID6 by human monocytes. 
Blood. 76:1392. 
32.  Aarden, L.A., E.R. de Groot, O.L. Schaap, and P.M. Lans- 
dorp. 1987. Production of hybridoma growth factor by human 
monocytes. Fur. j. Immunol.  17:1411. 
33.  Lonnemann, G., S. Endres,  J.W.M. Van der Meet, J.G. Cannon, 
K.M. Koch, and C.A. Dinarello. 1989. Differences in the syn- 
thesis and kinetics of release of interleukin lcz, interleukin 1/~ 
and tumor necrosis factor from human mononuclear cells. Eur. 
J. Immunol.  19:1531. 
34.  Helle, M., J.P.J. Brakenhoff, E.R. de Groot, and L.A. Aarden. 
1988. Interleukin 6 is involved in interleukin 1-induced activi- 
ties. Eur. J.  Immunol.  18:957. 
35.  Van Damme, J., S. Cayphas, G. Opdenakker, A. Billiau, and 
J. Van Snick. 1987. Interleukin 1 and poly(rI):poly(rC) induce 
production of a hybridoma growth factor by human fibroblasts. 
Eur. J. Immunol.  17:1. 
36.  Tosato, G.,  and  K.D.  Jones.  1990. Interleukin-1  induces 
interleukin-6 production in peripheral blood monocytes. Blood. 
75:1305. 
37.  Assoian, R.K., B.E. Fleurdelys, H.C. Stevenson, PJ. Miller, 
D.K. Madtes, E.W. Raines, R. Ross, and M.B. Sporn. 1987. 
Expression and secretion of type fl transforming growth factor 
by activated human macrophages. Proa Natl. Acad. $ci. USA. 
84:6020. 
38.  Essner, R., K. Rhoades, W.H. McBride, D.L. Morton, and 
J.S. Economou. 1989. IL-4  downregulates IL-1 and TNF gene 
expression in human  monocytes. J. Immunol.  142:3857. 
39.  Hart, P.H., G.F. Vitti, D.R. Burgess, G.A. Whitty, D.S. Pic- 
coli,  and J.A.  Hamilton.  1989. Potential antiinflammatory 
effects  of interleukin-4: suppression  of human monocyte tumor 
necrosis factor oe, interleukin-1  and prostaglandin  E2. Proc. 
Natl.  Acad. Sci. USA.  86:3803. 
40.  Donelly, R.P., M.J. Fenton, D.S. Finbloom, and T.L. Gerrard. 
1990. Differential regulation  of II--1 production in human 
monocytes by IFN-y and Ib4. J. Iramunol. 145:569. 
41.  Standiford, T.J., R.M. Strieter, S.W. Chensue, J. Westwick, 
K. Kasahara, and S.L. KunkeL 1990. IL-4 inhibits the expres- 
sion of 1I-,8 from stimulated human monocytes. J. Immunol. 
145:1435. 
42.  Dinarello, C.A.  1988. Biology of interleukin 1. FASEB (Fed. 
Am. Soc. Extx  Biol.) J.  2:108. 
43.  Kishimoto, T. 1989. Thebiology  ofinterleukin-6.  Blood. 74:1. 
44.  Baggiolini, M., A. Waltz, and S.L. Kunkel. 1989. Neutrophil- 
activating peptide-1/interleukin-8,  a novel cytokine that acti- 
vates neutrophils. J.  Clin. Invest. 84:1045. 
1220  Interleukin  10 Inhibits Monokine Production 